Mabwell prepares to showcase Phase II clinical data for its 9MW2821 ADC, marking a critical development step for its oncology portfolio in triple-negative breast cancer treatment.
Mabwell is set to present Phase II clinical data for its Nectin-4-targeting ADC, 9MW2821 (Bulumtatug Fuvedotin), which represents a critical milestone in the company's oncology pipeline. The presentation of this data is a significant event for investors as it provides evidence of the drug's efficacy and safety profile in treating triple-negative breast cancer, directly impacting the company's valuation and future commercial prospects.
9MW2821, also known as Bulumtatug Fuvedotin (BFv), is an antibody-drug conjugate (ADC) developed by Mabwell that targets Nectin-4.
The Phase II clinical data being presented focuses on the drug's application in treating triple-negative breast cancer.
Mabwell (688062.SH) announced it will unveil Phase II clinical trial results for its Nectin-4-targeting antibody-drug conjugate, 9MW2821. The data focuses on the drug's efficacy in treating triple-negative breast cancer, a key milestone for the company's oncology pipeline.
Mabwell is presenting Phase II clinical data for 9MW2821, an antibody-drug conjugate designed to target Nectin-4 for the treatment of triple-negative breast cancer.